Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199, Journal of Clinical Oncology, vol.32, issue.27, pp.2959-2966, 2014. ,
DOI : 10.1200/JCO.2013.55.0491
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann. Oncol. Off. J, 2014. ,
DOI : 10.1093/annonc/mdu191
URL : https://academic.oup.com/annonc/article-pdf/25/8/1536/16703445/mdu191.pdf
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer, Breast Cancer Research, vol.111, issue.51, 2016. ,
DOI : 10.1073/pnas.1415120112
Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, 2007. ,
DOI : 10.4049/jimmunol.173.1.307
URL : https://hal.archives-ouvertes.fr/hal-00316924
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J. Clin. Oncol, 2006. ,
DOI : 10.1200/jco.2005.04.1665
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Annals of Oncology, vol.26, pp.2429-2436, 2015. ,
DOI : 10.1093/annonc/mdv395
and (Francim), the F. network of cancer registries (2014). Cancer incidence and mortality in France over the 1980?2012 period: Solid tumors ,
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies, PLoS Medicine, vol.12, issue.5, 2010. ,
DOI : 10.1371/journal.pmed.1000279.s011
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2???Positive Operable Breast Cancer, Journal of Clinical Oncology, vol.23, issue.16, pp.3676-3685, 2005. ,
DOI : 10.1200/JCO.2005.07.032
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.45, issue.1, pp.181-187, 1989. ,
DOI : 10.1038/bjc.1979.139
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, 2014. ,
DOI : 10.1016/S0140-6736(13)62422-8
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer, Journal of Clinical Oncology, vol.28, issue.1, pp.105-113, 2010. ,
DOI : 10.1200/JCO.2009.23.7370
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2???Positive and Triple-Negative Primary Breast Cancers, Journal of Clinical Oncology, vol.33, issue.9, pp.983-991, 2015. ,
DOI : 10.1200/JCO.2014.58.1967
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study, Annals of Oncology, vol.25, issue.3, pp.611-618, 2014. ,
DOI : 10.1093/annonc/mdt556
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials, Annals of Oncology, vol.26, issue.8, 2015. ,
DOI : 10.1093/annonc/mdv239
Interferons, immunity and cancer immunoediting, Nature Reviews Immunology, vol.313, issue.11, pp.836-848, 2006. ,
DOI : 10.4049/jimmunol.175.9.5586
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update, Cancer, vol.152, issue.9, pp.1551-1557, 1983. ,
DOI : 10.1093/ajcp/65.4.439
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18., Journal of Clinical Oncology, vol.15, issue.7, pp.2483-2493, 1997. ,
DOI : 10.1200/JCO.1997.15.7.2483
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer, Breast Cancer Research, vol.109, issue.6, p.488, 2014. ,
DOI : 10.1073/pnas.1108781108
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2, Clinical Cancer Research, vol.10, issue.17, pp.5650-5655, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0225
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet, vol.375, issue.9712, pp.377-384, 2010. ,
DOI : 10.1016/S0140-6736(09)61964-4
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet Oncology, vol.15, issue.6, pp.640-647, 2014. ,
DOI : 10.1016/S1470-2045(14)70080-4
Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease, Journal of the American College of Surgeons, vol.208, issue.3, 2009. ,
DOI : 10.1016/j.jamcollsurg.2008.12.001
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Research, vol.69, issue.5, 2000. ,
DOI : 10.1158/0008-5472.CAN-08-2360
URL : http://cancerres.aacrjournals.org/content/canres/69/5/2000.full.pdf
The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Critical Reviews in Oncology/Hematology, vol.89, issue.2, pp.231-241, 2014. ,
DOI : 10.1016/j.critrevonc.2013.08.014
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort, British Journal of Cancer, vol.8, issue.1, pp.44-52, 2016. ,
DOI : 10.1200/JCO.2006.09.2775
URL : http://www.nature.com/bjc/journal/v114/n1/pdf/bjc2015426a.pdf
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status, JNCI: Journal of the National Cancer Institute, vol.106, issue.5, 2014. ,
DOI : 10.1093/jnci/dju055
URL : https://academic.oup.com/jnci/article-pdf/106/5/dju055/17313523/dju055.pdf
Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2- positive breast cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, 2016. ,
Annual Report to the Nation on the Status of Cancer, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J. Natl. Cancer Inst, p.48, 1975. ,
Natural and therapy-induced immunosurveillance in breast cancer, Nature Medicine, vol.75, issue.10, pp.1128-1138, 2015. ,
DOI : 10.1038/nm.3773
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.17, issue.2, pp.460-469, 1999. ,
DOI : 10.1200/JCO.1999.17.2.460
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing, Cancer Immunology, Immunotherapy, vol.309, issue.11, pp.1887-1896, 2009. ,
DOI : 10.1007/s00262-009-0700-0
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, The Journal of Pathology, vol.5, issue.3, pp.389-400, 2011. ,
DOI : 10.1038/nrc1613
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival, British Journal of Cancer, vol.23, issue.3, pp.366-371, 2011. ,
DOI : 10.1038/nri1936
URL : http://www.nature.com/bjc/journal/v105/n3/pdf/bjc2011261a.pdf
Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer, Acta Oncologica, vol.65, issue.1, pp.232-238, 2008. ,
DOI : 10.1016/j.ijrobp.2005.12.014
Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.15, issue.2, pp.239-249, 2015. ,
DOI : 10.1016/S1470-2045(13)70477-7
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Annals of Oncology, vol.25, issue.8, pp.1544-1550, 2014. ,
DOI : 10.1093/annonc/mdu112
T lymphocytes infiltrating breast cancer, OncoImmunology, vol.58, issue.3, pp.364-365, 2012. ,
DOI : 10.1016/j.cell.2011.02.013
URL : http://www.tandfonline.com/doi/pdf/10.4161/onci.18614?needAccess=true
The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis, PLoS ONE, vol.73, issue.3, 2014. ,
DOI : 10.1371/journal.pone.0115103.s005
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis, PLOS ONE, vol.26, issue.2, 2016. ,
DOI : 10.1371/journal.pone.0152500.s008
New insights into cancer immunoediting and its three component phases???elimination, equilibrium and escape, Current Opinion in Immunology, vol.27, pp.16-25, 2014. ,
DOI : 10.1016/j.coi.2014.01.004
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388310/pdf
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis, Genome Biology, vol.14, issue.4, p.34, 2013. ,
DOI : 10.1158/1078-0432.CCR-06-2765
URL : https://genomebiology.biomedcentral.com/track/pdf/10.1186/gb-2013-14-4-r34?site=genomebiology.biomedcentral.com
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group., Journal of Clinical Oncology, vol.10, issue.5, pp.696-705, 1992. ,
DOI : 10.1200/JCO.1992.10.5.696
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Research and Treatment, vol.26, issue.10, pp.793-805, 2012. ,
DOI : 10.1080/07357900802098165
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers, Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers, J, 2014. ,
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity, Cancer Cell, vol.18, issue.2, pp.160-170, 2010. ,
DOI : 10.1016/j.ccr.2010.06.014
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31, Journal of Clinical Oncology, vol.29, issue.25, 2011. ,
DOI : 10.1200/JCO.2011.35.0868
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer, JAMA Oncology, vol.2, issue.1, pp.56-64, 2016. ,
DOI : 10.1001/jamaoncol.2015.3239
CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients, Clinical Cancer Research, vol.13, issue.9, pp.2714-2721, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2347
URL : http://clincancerres.aacrjournals.org/content/clincanres/13/9/2714.full.pdf
Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000. ,
DOI : 10.1038/35021093
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, Journal of Clinical Oncology, vol.26, issue.5, pp.778-785, 2008. ,
DOI : 10.1200/JCO.2007.15.0235
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy, Clinical Cancer Research, vol.11, issue.16, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2421
URL : http://clincancerres.aacrjournals.org/content/clincanres/11/16/5678.full.pdf
Adjuvant role for cell death during chemo- and radiotherapy of cancer?, Expert Review of Clinical Immunology, vol.14, issue.1, pp.27-32, 2008. ,
DOI : 10.1038/sj.cdd.4402148
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Annals of Oncology, vol.26, issue.2, pp.259-271, 2015. ,
DOI : 10.1093/annonc/mdu450
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab, JAMA Oncology, vol.1, issue.4, pp.448-454, 2015. ,
DOI : 10.1001/jamaoncol.2015.0830
URL : http://oncology.jamanetwork.com/data/journals/oncology/934193/coi150025.pdf
Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161???708 Cases of Breast Cancer From the SEER Program, Archives of Pathology & Laboratory Medicine, vol.138, issue.8, pp.1048-1052, 2014. ,
DOI : 10.5858/arpa.2013-0435-OA
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer, British Journal of Cancer, vol.177, issue.10, pp.2705-2713, 2013. ,
DOI : 10.1172/JCI35180
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy, Annals of Oncology, vol.26, issue.1, 2015. ,
DOI : 10.1093/annonc/mdu508
URL : https://academic.oup.com/annonc/article-pdf/26/1/75/19480983/mdu508.pdf
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity, J. Immunol. Baltim. Md, vol.163, pp.5211-5218, 1950. ,
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, The Lancet, vol.369, issue.9555, pp.29-36, 2007. ,
DOI : 10.1016/S0140-6736(07)60028-2
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad, 2001. ,
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5838-5847, 2009. ,
DOI : 10.1200/JCO.2009.22.1507
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, pp.323-334, 2008. ,
DOI : 10.1016/j.breast.2008.02.002
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.25, issue.28, 2007. ,
DOI : 10.1200/JCO.2007.10.6823
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study, Journal of Clinical Oncology, vol.28, issue.12, 2010. ,
DOI : 10.1200/JCO.2009.23.8451
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer, Clinical Cancer Research, vol.22, issue.13, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-2021
URL : http://clincancerres.aacrjournals.org/content/clincanres/22/13/3249.full.pdf
Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer, British Journal of Cancer, vol.5, issue.1, pp.155-162, 2013. ,
DOI : 10.1371/journal.pone.0014282
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553524/pdf
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18, JNCI Monographs, vol.2001, issue.30, pp.96-102, 2001. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003469